--- title: "MAIA Biotechnology (MAIA) news: going concern and offering" url: "https://aibio.space/companies/maia-biotechnology/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "MAIA going concern and offering news: MAIA Biotechnology prices $1.43 million private placement of shares and warrants. MAIA Biotechnology, Inc." --- MAIA MAIA Biotechnology, Inc. AMEX · United States # MAIA Biotechnology (MAIA) news MAIA going concern and offering news Financings · 2025-05-28 ## [MAIA Biotechnology agrees to $695,000 private placement with warrants](https://aibio.space/news/maia-biotechnology-agrees-695-000-private-placement-warrants/) MAIA Biotechnology (NYSE American: MAIA) expects gross proceeds of approximately $695,000 from shares sold at $1.50 with warrants at $1.71. A director is among the buyers, and closing is expected May 29, 2025. ## Latest MAIA Biotechnology news 1. 2025-03-26 Financings [MAIA Biotechnology cuts at-the-market program to $11,200,000 from $30,000,000](https://aibio.space/news/maia-biotechnology-cuts-market-program-11-200-000-30-000-000/) The smaller size reflects an SEC limit tied to MAIA's public float. The company has sold about $11,633,086 of stock under the agreement so far. 2. 2025-02-25 Financings [MAIA Biotechnology prices $1.43 million private placement of shares and warrants](https://aibio.space/news/maia-biotechnology-prices-1-43-million-private-placement-shares/) MAIA Biotechnology agreed on February 24, 2025 to sell 894,300 shares at $1.50 each, with warrants at $1.85, to accredited investors and certain directors. Combined gross proceeds are expected to be about $1.43 million, and the company's 2023 annual report carried a going-concern warning. ## MAIA Biotechnology at a glance - **Ticker**: MAIA - **Listing**: AMEX - **Country**: United States - **Cash, Jun 30, 2026**: $0 ### Related companies - [OS Therapies](https://aibio.space/companies/os-therapies/) AMEX: OSTX - [Xeris Biopharma Holdings](https://aibio.space/companies/xeris-biopharma/) NASDAQ: XERS - [Axsome Therapeutics](https://aibio.space/companies/axsome-therapeutics/) NASDAQ: AXSM - [SAB Biotherapeutics](https://aibio.space/companies/sab-biotherapeutics/) NASDAQ: SABS - [BioCardia](https://aibio.space/companies/biocardia/) NASDAQ: BCDA - [Palvella Therapeutics](https://aibio.space/companies/palvella-therapeutics/) NASDAQ: PVLA - [Neurocrine Biosciences](https://aibio.space/companies/neurocrine-biosciences/) NASDAQ: NBIX - [Halberd](https://aibio.space/companies/halberd/) OTC: HALB ### Also on AMEX - [Matinas Biopharma Holdings](https://aibio.space/companies/matinas-biopharma/) MTNB - [OS Therapies](https://aibio.space/companies/os-therapies/) OSTX - [IGC Pharma](https://aibio.space/companies/igc-pharma/) IGC - [China Pharma Holdings](https://aibio.space/companies/china-pharma/) CPHI - [Azitra](https://aibio.space/companies/azitra/) AZTR - [Lineage Cell Therapeutics](https://aibio.space/companies/lineage-cell-therapeutics/) LCTX ## What MAIA Biotechnology does MAIA Biotechnology is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Its lead asset, ateganosine (THIO), is an investigational dual mechanism of action drug candidate that incorporates telomere targeting and immunogenicity. Ateganosine is being developed as a second- or later-line treatment for advanced non-small cell lung cancer (NSCLC) in patients who have progressed beyond existing checkpoint inhibitors. The Phase 2 THIO-101 trial, first dosed in Australia in July 2022, evaluates ateganosine given in sequence with cemiplimab (Libtayo), which the company receives at no cost from Regeneron under a clinical supply agreement. In July 2025 the company began an expansion of THIO-101 focused on third-line NSCLC patients. The company plans to seek accelerated approval in the United States for advanced NSCLC in 2026, based on THIO-101 data. A Phase 3 pivotal trial, THIO-104, started in 2025 and is designed for a direct comparison with chemotherapy in up to 300 patients. The former Phase 2 program THIO-102 has been divided into separate trials in hepatocellular carcinoma, colorectal cancer and small cell lung cancer, with trials planned to start in 2026 using tislelizumab from BeOne Medicines. | Product or program | What it is | Stage | |---|---|---| | Ateganosine (THIO-101) | Telomere-targeting immunotherapy for advanced NSCLC after checkpoint inhibitors | Phase 2; fast track designation granted July 2025 | | Ateganosine (THIO-104) | Ateganosine with a checkpoint inhibitor versus chemotherapy in third-line NSCLC | Phase 3 pivotal trial started in 2025 | | Ateganosine (HCC, CRC, SCLC) | Ateganosine with tislelizumab in liver, colorectal and small cell lung cancers | Phase 2 trials planned to start in 2026 | Summarised from the company's [10-K filed Mar 23, 2026](https://www.sec.gov/Archives/edgar/data/1878313/000149315226012088/form10-k.htm). ## MAIA Biotechnology annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | | [$0](https://www.sec.gov/Archives/edgar/data/1878313/000095017025043190/) | | Research and development | [$453,745](https://www.sec.gov/Archives/edgar/data/1878313/000149315226012088/) | [$10.0 million](https://www.sec.gov/Archives/edgar/data/1878313/000095017025043190/) | | Net income (loss) | [-$22.4 million](https://www.sec.gov/Archives/edgar/data/1878313/000149315226012088/) | [-$23.3 million](https://www.sec.gov/Archives/edgar/data/1878313/000149315226012088/) | | Cash from operations | [-$18.8 million](https://www.sec.gov/Archives/edgar/data/1878313/000149315226012088/) | [-$15.7 million](https://www.sec.gov/Archives/edgar/data/1878313/000149315226012088/) | | Cash and equivalents | [$0](https://www.sec.gov/Archives/edgar/data/1878313/000149315226036764/) | [$0](https://www.sec.gov/Archives/edgar/data/1878313/000149315226012088/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $0. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about MAIA Biotechnology Has MAIA Biotechnology issued a going-concern warning? Our latest story on this, dated Feb 25, 2025: "MAIA Biotechnology prices $1.43 million private placement of shares and warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/maia-biotechnology-prices-1-43-million-private-placement-shares/). Has MAIA Biotechnology raised money recently? Our latest story on this, dated May 28, 2025: "MAIA Biotechnology agrees to $695,000 private placement with warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/maia-biotechnology-agrees-695-000-private-placement-warrants/). What is the ticker symbol of MAIA Biotechnology? MAIA Biotechnology, Inc. trades under the ticker MAIA on AMEX. Where is MAIA Biotechnology listed? MAIA Biotechnology, Inc. is listed on AMEX. What is the SEC CIK of MAIA Biotechnology? The SEC Central Index Key (CIK) for MAIA Biotechnology, Inc. is 1878313. Its filings are on SEC EDGAR. How many shares does MAIA Biotechnology have outstanding? 60,825,844 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is MAIA Biotechnology listed under? Our directory records MAIA Biotechnology, Inc. under United States. What does MAIA Biotechnology do? Our directory classifies MAIA Biotechnology, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of MAIA Biotechnology? The ISIN recorded for MAIA Biotechnology, Inc. is US5526411021. Does aibio.space cover MAIA Biotechnology? aibio.space lists MAIA Biotechnology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is MAIA Biotechnology incorporated? SEC records list its state or country of incorporation as DE. What does MAIA Biotechnology develop? MAIA Biotechnology is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Its lead asset, ateganosine (THIO), is an investigational dual mechanism of action drug candidate that incorporates telomere targeting and immunogenicity. What is Ateganosine (THIO-101) from MAIA Biotechnology? Ateganosine (THIO-101): Telomere-targeting immunotherapy for advanced NSCLC after checkpoint inhibitors Stage: Phase 2; fast track designation granted July 2025. What is Ateganosine (THIO-104) from MAIA Biotechnology? Ateganosine (THIO-104): Ateganosine with a checkpoint inhibitor versus chemotherapy in third-line NSCLC Stage: Phase 3 pivotal trial started in 2025. Is MAIA Biotechnology profitable? MAIA Biotechnology, Inc. reported a net loss of $22.4 million for the fiscal year ended Dec 31, 2025, and used $18.8 million of cash in operations, per its annual report to the SEC. ## Investor discussion: MAIA Biotechnology Members talk about MAIA Biotechnology (MAIA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at MAIA Biotechnology, newest first. Each line links the filing it comes from. 1. 2026-05-14 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1878313/000149315226023160/form424b5.htm) 2. 2026-05-14 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1878313/000149315226023168/form8-k.htm) 3. 2025-03-26 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1878313/000164117225000776/form424b5.htm) 4. 2024-12-23 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1878313/000119312524284258/d698846d424b5.htm) 5. 2024-12-10 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1878313/000119312524273921/d899097dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:MAIA on TradingView](https://www.tradingview.com/symbols/AMEX-MAIA/). ## SEC filings and registration - **SEC name**: MAIA Biotechnology, Inc. - **CIK**: 1878313 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: MAIA (NYSE) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL, 60606 - **Phone**: 312-416-8592 - **Shares outstanding**: 60,825,844 as of 2026-08-10 (10-Q filed 2026-08-10) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1878313/000149315226045865/form8-k.htm) filed 2026-10-06 - [S-3](https://www.sec.gov/Archives/edgar/data/1878313/000149315226044361/forms-3.htm) filed 2026-09-25 - [S-3](https://www.sec.gov/Archives/edgar/data/1878313/000149315226039679/forms-3.htm) filed 2026-08-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1878313/000149315226036764/form10-q.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1878313/000149315226024884/form8-k.htm) filed 2026-05-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1878313/000149315226023168/form8-k.htm) filed 2026-05-14 - [424B5](https://www.sec.gov/Archives/edgar/data/1878313/000149315226023160/form424b5.htm) filed 2026-05-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1878313/000149315226022154/form10-q.htm) filed 2026-05-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001878313), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details MAIA Biotechnology, Inc. is a public biotech or pharmaceutical company listed on AMEX under the ticker MAIA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: MAIA Biotechnology, Inc. - **Ticker**: MAIA - **Listing**: AMEX - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US5526411021 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-MAIA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/maia-biotechnology/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "MAIA Biotechnology (MAIA) news: going concern and offering", 2026-10-31, https://aibio.space/companies/maia-biotechnology/